What’s the actual difference between BPC-157 and TB-500 for healing?

BPC-157 is a 15-amino-acid peptide studied in injury models involving blood-vessel formation, inflammation, and tendon-cell behavior. Thymosin beta-4 is a different, 43-amino-acid molecule that binds actin, a protein involved in cell structure and movement. Experiments with thymosin beta-4 and its actin-binding fragment suggest effects on cell migration and wound repair. These are overlapping biological themes, not proof that one is a “local healer” and the other a “systemic healer.”[1][2]

The name TB-500 needs particular care. FDA identifies TB-500 as the thymosin beta-4 fragment LKKTETQ, while commercial usage of the name is inconsistent. Results for full-length thymosin beta-4, including topical wound studies, cannot automatically be applied to an injectable fragment or a product whose actual sequence is unclear. The exact molecule, formulation, and injury matter more than the marketing name.[2][3]

There is no established human evidence that combining BPC-157 and TB-500 repairs injuries better than either alone, or that either reliably heals a torn labrum. Different proposed pathways do not demonstrate synergy, and overlapping pathways do not establish redundancy. Answering whether both are needed would require controlled human comparisons with structural healing, function, and safety outcomes; current mechanism diagrams cannot settle it.[1][2][3]